Posted by Michael Wonder on 22 Oct 2025
Clascoterone for the treatment of patients 12 years of age and older with acne vulgaris
22 October 2025 - NICE is unable to make a recommendation on the use of clascoterone (Winlevi) for the treatment of patients 12 years of age and older with acne vulgaris because Glenmark Pharmaceuticals did not provide an evidence submission.
NICE will review this decision if Glenmark Pharmaceuticals decides to make a submission.
